Recruiting has started for a clinical trial sponsored by Aurora Cannabis and directed by Dr. Mark Levine, an internationally recognized cancer clinician, researcher and Order of Canada recipient.
The ultimate goal is to improve pain management for patients suffering breast, prostate or gastrointestinal cancer.
The clinical trial will assess the effect of cannabis oil in relieving cancer-pain symptoms and provide information on the best oral dosing regimen.
MedReleaf capsules, containing whole-plant cannabis-oil extract (CBD and TCH), will be orally administered along with existing treatment regimens, including opioid medicine.
“Anecdotally, cancer patients have been telling us that cannabis products help their pain,” said the study’s principal investigator Dr. Marissa Slaven, a specialist in pain management and palliative care.
Thanks to MedReleaf’s commitment to advancing medical science, we will now be able to start gathering the data needed to help our patients live better.”
The Ontario Clinical Oncology Group and Hamilton Health Sciences @HamHealthSci are collaborating with Aurora for the clinical trial, which will be dircted at the HHS Juravinski Cancer Centre in Hamilton, Ontario.
Approximately 40 patients will participate in the study over a one-to-two-year period.
Other clinical trials sponsored by Aurora
Aurora’s CanniMed cannabis-oil will be used in a clinical trial funded by Parkinson Society Canada.
In August, the company announced an international research project led by McGill University to examine the potential of CanniMed CBD oil to treat chronic pain and related anxiety and depression.
The company also announced the launch of its CanniMed line of hard-shell capsules that deliver equal concentrations of THC and CBD (3mg/capsule of each).